


Business Stockhead

ASX healthcare stocks riding the point-



Lumos and Atomo are making waves in point-of-care testing. Pic: Getty Images

Point-of-care testing emerges as one of the most disruptive shifts in global diagnostics



But long before Covid-19 POC testing was already bringing medical diagnostics out of laboratories and into GP clinics, pharmacies and homes leading to faster results and treatment. Analysts see roadblocks for AI copper narrative. Morningstar has issued a warning that community backlash could data centre growth and hurt bullish AI-related copper demand projections. Developed in the late 1970s home pregnancy tests were among the first widely adopted POC diagnostics, allowing women to receive accurate results within minutes with ovulation tests following.

In the 1980s finger-prick blood glucose monitors became widely available, transforming diabetes care by enabling people to check their blood sugar levels in seconds.



The test aims to help reduce the inappropriate and unnecessary use of antibiotics, recognised as a key driver of the growing global public health challenge of antimicrobial resistance (AMR).

Morning Feed: What's cooking on the ASX?

Morning Feed plates up early sharemarket movers, announcements and company news, serving investors a quick hit of market action and updates from selected ASX-listed companies.

Lumos chief executive Doug Ward told *Stockhead* the test gave clinicians greater confidence while the patient was still in the consulting room.

FebriDx is a 10-minute, finger-stick point-of-care test that distinguishes

between bacterial, typically viral, respiratory infections," Ward said.



commercial milestone came earlier this year when it secured a [Clinical Laboratory Improvement Amendments \(CLIA\) waiver](#)

Blood split as chair, directors ousted at iconic Aussie company
Mayfair Hotel to be transformed after \$75m sale
Digital air traffic control towers not fit for VFR, says American boss

Ward said FebriDx was the only CLIA-waived, instrument-free point-of-care test in the US that differentiated bacterial from non-bacterial respiratory infections across the full spectrum of respiratory illnesses rather than

Good Afternoon George Recommended based on what you've read



appropriate antibiotic prescribing into the point-of-care workflow.

\$21m drug haul as eight charged in crime
Inside Donald Trump's new flying palace
One word leaving entire region on edge

Commercial rollout is underway after Lumos signed a six-year exclusive national US distribution agreement worth ~US\$317 million with PHASE

Scientific

Trending now

Read More

"PHASE has in turn established sub-distribution relationships with Henry Schein, McKesson, NDC and others, representing more than 2,000 trained

rep. "Ward said, "Our own and PHASE's field teams are hyper-focused on the top 100 urgent care parent entities, which alone account for roughly half of all US urgent care sites, while partners like Henry Schein and McKesson cover the long tail of smaller practices."

commentary problem

care parent entities, which alone account for roughly half of all US urgent care sites, while partners like Henry Schein and McKesson cover the long tail of smaller practices."

Justice Dept. says justice denied': Vets demand and to war crimes investigation

This is a capital-efficient way to move the needle where volumes and influence are highest."



Taylor and Travis spark traffic mayhem amid new wedding plot twist



Motoring News



'Serious': Car brands tipped to exit Aus

Use of FebriDx is also being established within the WellStreet Urgent Care network.

Commercial Real Estate

\$100m burger empire's huge Aussie rollout

"WellStreet is a good example of how we approach large urgent care accounts," Ward said.

Sydney Weekend

"We started by piloting FebriDx at a single, moderately complex WellStreet site in Fayetteville, Georgia, before CLIA waiver, to prove clinical value and refine how the test fits into the workflow," Ward said.

The fear is real': Darren Robertson on life as a

"After CLIA waiver, that pilot expanded to more than 40 sites and is now scaling across the broader WellStreet footprint in multiple states."

National

'I was broke': 32yo

Ward said FebriDx now had the regulatory clearance, clinical evidence, economic rationale and commercial infrastructure to become a standard POC tool for managing acute respiratory infections.

Aussie made \$1m in 6 months

Stockhead

"The next respiratory season is about converting that foundation into visible, repeat utilisation and revenue across a growing base of high-value accounts."

Follow

Beyond FebriDx, Lumos is also involved in a range of POC development programs through commercial and technical collaborations.

Atomo grows supply partnerships and in-house tests

[Atomo Diagnostics \(ASX:AT1\)](#) powers part of the POC testing supply chain, but also develops and commercialises its own rapid diagnostic tests.

Its Pascal platform is used to make single-use test cassettes for rapid blood testing outside traditional laboratories.

The design is focused on improving ease of use, consistency and suitability for testing in clinics, pharmacies and other POC environments.

A key commercial relationship is its role as a supplier of these test cassettes to Lumos for their FebriDx test.

Atomo has an established presence in infectious disease testing, including HIV self-tests in markets such as Australia, New Zealand and the UK.

It has also developed a rapid syphilis test, targeting a sexually transmitted infection (STI) that has re-emerged as a growing public health concern in several developed markets, including Australia and the US, after years of decline.

The company also has early-stage programs in liver health testing. Atomo said recent new customers reflected growing interest in its test solutions as a scalable foundation for rapid diagnostic test development including self-testing at home.

Shift beyond POC testing to remote monitoring

While point-of-care testing continues to expand, [Adherium \(ASX:ADR\)](#) sits within a broader shift toward remote monitoring and decentralised healthcare.

Adherium's FDA-cleared Hailie Smartinhaler targets poor medication adherence in respiratory medicine, which is a key driver of avoidable flare-ups, hospitalisations and declining disease control.

Chief commercial officer John Perry told *Stockhead* the device attached to standard asthma and COPD inhalers, automatically recording when medication was taken and capturing real-world usage data between clinical visits.

"Most adherence programs fail because they depend on the patient adopting a new habit," he said.

"Ours does not because capture is passive, so the data keeps flowing even from the older, disengaged, hard-to-reach patients who need it most.

"On that foundation, care moves off patient recall and the occasional in-clinic snapshot and onto objective, real-world data captured between visits.

Perry said the data provided from the Hailie Smartinhaler was already changing clinical decisions.

"Clinicians see whether controller medication is actually being taken, whether reliever use is climbing and whether technique is the real problem," he said.

He said it then became a matter of "coach or prescribe" where care teams could tell whether the fix was a technique correction or a medication change.

And rather than adding another monitoring task for stretched clinicians, Adherium operates a managed care model where its team monitors adherence data, engages patients between appointments and escalates only clinically significant cases.

"Routine support is handled remotely, and only the patients who need clinical review reach the clinician," Perry said.

Adherium is also building a strong case for adoption, backed by clinical evidence from its iCARE program with Intermountain Health, based in Utah in the US, which has deployed 4,000 Hailie Smartinhalers across up to 2500 asthma and COPD patients in five healthcare facilities.

"Patients on Hailie-connected controllers used them as prescribed roughly two-thirds of the time, against the one-in-five typically reported in this population," Perry said.

"Nearly four in 10 cleared 80% adherence, the threshold associated with roughly half as many respiratory attacks."

The improvement translated into a 50.3% reduction in hospital admissions, a 20% reduction in emergency department visits and a 57% fall in annual cost of care per patient, from US\$36,837 to US\$15,899. Patient engagement remained high, with retention above 90% at 12 months.

Perry said moves to value-based care, where providers were paid for outcomes rather than activity, was driving a new commercial model well suited to Adherium.

"The iCARE cost-of-care reductions are exactly what health systems and payers now buy under value-based reimbursement," he said.

"So this is not a pivot away from revenue. It is the path to larger, stickier, outcomes-linked revenue, and to Adherium becoming a digital respiratory care partner rather than a connected device company."

This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

At Stockhead we tell it like it is. While Lumos Diagnostics is a Stockhead advertiser, the company did not sponsor this article.

Originally published as [ASX healthcare stocks riding the point-of-care testing wave](#)

Membership	About Us	Contact Us	Our News Network	Our Partners	Our Apps
Subscription Packages	About us	Help & support	Herald Sun	Buy Search Sell Classifieds	 
Group/Corporate subscriptions	Meet the team	FAQs	Courier Mail	Find Your Local	
The Daily Telegraph app	Job opportunities	Standards of practice	The Advertiser	Foxsports	
Today's Paper	Code of conduct	Letter to the Editor	news.com.au	Foxtel	
Newsletters	Subscriptions FAQs	Licensing & Reprints	The Australian	Hipages	
	Subscription terms	Advertise with us	The Mercury	Kayo	
	Financial Hardship Policy		Geelong Advertiser	My Tributes	
			Punters	odds.com.au	
			The Cairns Post	racenet.com.au	
			Gold Coast Bulletin	realestate.com.au	
			Townsville Bulletin	Sky News	
			The Chronicle	Coupons	
			NT News		

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times AEST (GMT +10). Powered by WordPress.com VIP

[Privacy policy](#)

[Relevant ads opt-out](#)

[Cookie policy](#)

[Terms of use](#)